1 Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin

2 Long term follow-up of children hospitalized with respiratory syncytial virus lower respiratory tract infection and randomly treated with ribavirin or placebo

3 Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation

4 Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression

5 Ribavirin for respiratory syncytial virus lower respiratory tract infection. A systematic overview

6 Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections. American Academy of Pediatrics Committee on Infectious Diseases

7 Effectiveness of ribavirin in otherwise well infants with respiratory syncytial virus-associated respiratory failure. Pediatric Critical Study Group

8 Telaprevir for previously untreated chronic hepatitis C virus infection

9 Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons. A double-blind, placebo-controlled trial

10 A randomised placebo controlled trial of suppressive acyclovir in late pregnancy in women with recurrent genital herpes infection

11 Acyclovir suppression to prevent cesarean delivery after first-episode genital herpes

12 Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment

13 The antiviral activity of SP-303, a natural polyphenolic polymer, against respiratory syncytial and parainfluenza type 3 viruses in cotton rats

14 Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group

15 Boceprevir for untreated chronic HCV genotype 1 infection

16 Reducing the morbidity of lower respiratory tract infections caused by respiratory syncytial virus: still no answer

17 Does ribavirin impact on the hospital course of children with respiratory syncytial virus (RSV) infection? An analysis using the pediatric investigators collaborative network on infections in Canada (PICNIC) RSV database

18 Follow-up of children with respiratory syncytial virus bronchiolitis in 1986 and 1987: potential effect of ribavirin on long term pulmonary function. The Bronchiolitis Study Group

19 Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients

20 Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus

21 Belgian experience with direct acting antivirals in people who inject drugs

22 Hepatitis C Virus-Infected Patients Receiving Opioid Substitution Therapy Experience Improvement in Patient-Reported Outcomes Following Treatment With Interferon-Free Regimens

23 Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial

24 Initial outcomes of integrated community-based hepatitis C treatment for people who inject drugs: Findings from the Queensland Injectors' Health Network

25 Monitoring of neuraminidase inhibitor resistance among clinical influenza virus isolates in Japan during the 2003-2006 influenza seasons

26 Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: a retrospective case-control study

27 Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial

28 Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials

29 Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis

30 Treatment of influenza with neuraminidase inhibitors: virological implications

31 Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: A prospective study

32 An In-Depth Analysis of Patient-Reported Outcomes in Patients With Chronic Hepatitis C Treated With Different Anti-Viral Regimens

33 Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis

34 Real-world effectiveness and predictors of sustained virological response with all-oral therapy in 21,242 hepatitis C genotype-1 patients

35 Factors associated with early hospital discharge of adult influenza patients

36 Oral oseltamivir treatment of influenza in children

37 Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice

38 Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults

39 Regression of Hodgkin lymphoma in response to antiviral therapy for hepatitis C virus infection

40 In vitro and in vivo sensitivity of a non-mouse-adapted influenza A (Beijing) virus infection to amantadine and ribavirin

41 Chronic hepatitis B

42 Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice?

43 Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C

44 Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents

45 In vitro and in vivo activities of anti-influenza virus compound T-705

46 Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods

47 Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

48 Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses

49 Sofosbuvir for previously untreated chronic hepatitis C infection

50 The influence of hepatitis B virus on antiviral treatment with interferon and ribavirin in Asian patients with hepatitis C virus/hepatitis B virus coinfection: a meta-analysis

51 Understanding real-world adherence in the directly acting antiviral era: A prospective evaluation of adherence among people with a history of drug use at a community-based program in Toronto, Canada

52 Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice

53 A severe hepatitis flare in an HBV-HCV coinfected patient during combination therapy with alpha-interferon and ribavirin

Keyword Connections

Journals

Research Groups

Bibliographies